Trial Profile

A Two-part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Oral Doses of Pazopanib in Healthy Adult Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 25 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pazopanib (Primary)
Indications Acute myeloid leukaemia; Age-related macular degeneration; Bladder cancer; Breast cancer; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Fallopian tube cancer; Gallbladder cancer; Glioma; Hereditary haemorrhagic telangiectasia; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Renal cancer; Sarcoma; Solid tumours; Thyroid cancer
Focus Adverse reactions
Sponsors GlaxoSmithKline; GSK

Most Recent Events

16 Sep 2015 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com